Experimental drug aims to boost immune attack on aggressive brain tumors
NCT ID NCT07301268
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells inside the tumor and shrink it, making surgery more effective. About 36 adults will take part, and researchers will measure changes in the tumor's immune environment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GI-102 (a bispecific fusion protein) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, potentially improving immune response against the tumor.
What could go wrong
This is a small, early-phase trial (36 participants) focused on immune changes, not yet on survival or cure. The drugs may not work or could cause side effects like immune-related inflammation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.